In conclusion, this descriptive review of HDMTX courses in the treatment of children with ALL has shown that hypoalbuminemia is a frequent occurrence when therapy with ASP is ongoing, and that it has a significant impact on MTX pharmacokinetics, depending on the degree of albumin suppression. This evidence concerns the gene ALB and Hypoalbuminemia.